Diagnosing chronic kidney disease (CKD) earlier can help reduce the need for dialysis. This would lower the environmental impact of CKD by reducing the need for fresh water and electricity, lessening carbon emissions and healthcare waste.
Learn more: learn.az/6012bciYM

We’re committed to reducing our impact on the planet. This includes reducing the environmental burden of plastics. Wherever possible, we look to incorporate a circular approach into our processes and product designs – from lab to patient: learn.az/6018bwRIe

#EarthDay

Diagnosing and treating chronic kidney disease in its early stages could reduce costs and preserve health systems’ resources, allowing investment to be redirected to other areas of need. Make the change for kidney health by visiting: learn.az/6019wbbbN

AstraZeneca recognised with two Reuters awards 🎉

We’re delighted to win both the ‘Driving Health Equity’ and ‘Sustainability’ categories at #REPHarma2024 this week for our Young Health Programme and Electronic Product Information.

Thank you, Reuters, for the recognition.

New modelling evidence presented at #WCN24 predicts the percentage of the population with chronic kidney disease by 2032 as up to 16.5% across 8 countries. Let’s change this outcome.

Get involved to make a change #ForKidneyHealth by visiting learn.az/6017b6PWR

Chronic kidney disease (CKD) is life-changing and can become very serious if left untreated. Earlier detection and treatment of CKD can improve patients’ health-related quality of life. Learn the difference a change can make learn.az/6016wXpq0 #ForKidneyHealth

Good health is at the heart of a sustainable future.

We’re transforming healthcare to secure a future where all people have access to affordable, sustainable and innovative care: learn.az/6017wD5LV
🩺

#MyHealthMyRight

We have the power to make the change for kidney health and improve the lives of patients, caregivers, healthcare systems, the economy and the environment.

Take kidney change into your own hands by visiting: learn.az/6010ZAcMq

#ForKidneyHealth

On 16 April, 15:00–16:00 CEST, hear from experts on how electronic product information can provide accessible, environmentally sustainable medicine information.

Sign up for our free webinar: us02web.zoom.us/webinar/regist…

#policymakers #regulators #DigitalHealth

We’ve announced a pioneering clean heat partnership with China Resources Gas and Everbright Environment to decarbonise the manufacture medicines at our Wuxi site in China.

Discover more: learn.az/6016ZV9Gi

We are calling on policymakers to elevate chronic kidney disease as an urgent global health priority to help create positive change. Make the change #ForKidneyHealth : learn.az/6017ZPhxc

We continue to develop evidence to empower nephrologists, cardiologists, and primary healthcare providers to achieve guideline directed medical care to optimise cardiorenal protection for hyperkalaemia patients. Learn more: learn.az/6011kCKYc

We’re investing in nature and #WaterStewardship to drive positive impact.

To scale action, we partnered with @BioPhorum on a new publication to support the shift to water stewardship for the biopharma industry: learn.az/6013kCzmT

#WorldWaterDay

Momentum is building to transform lupus care, with EULAR recommendations prioritising earlier intervention with optimised therapy.

Let’s forge a brighter future for those living with lupus and make remission a reality:
learn.az/6015kUbBD
#LUPUS2024

People with COPD face increased risk of lung and heart events. This cardiopulmonary risk is elevated after a COPD exacerbation and can last for up to a year. Profs. Chris Gale and Frederik Trinkmann explore how proactive COPD care could address this: learn.az/6013kkOAc

Earlier detection of CKD can improve patient outcomes, limiting the impact on health systems, caregivers, economies and the environment. We must create a future where the nearly 850 million people worldwide affected by CKD can live better, healthier lives. learn.az/6017kHmCP

Intended for investors:

We have entered into a definitive agreement to acquire Amolyt Pharma, further expanding our late-stage rare disease pipeline. Learn more about the financial considerations here: learn.az/6019kTK63

We’re taking joint, scalable action to accelerate the delivery of net zero healthcare alongside public and private members of The Sustainable Markets Initiative Health Systems Task Force.

Our work is highlighted in the latest The Sustainable Markets Initiative Impact Report: learn.az/6019krUCb.